



X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

November 14, 2024

BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- [X4 Pharmaceuticals](#) (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will participate in the Stifel 2024 Healthcare Conference, taking place in New York, NY on November 18-19, 2024.

Stifel 2024 Healthcare Conference

Date: Monday, November 18, 2024

Time: 4:10PM ET

Format: Fireside Chat

Location: Lotte New York Palace, New York

[Webcast Link](#)

A link for this live webcast will also be accessible through the "[events & presentations](#)" page in the investors section of X4 Pharmaceuticals' website. After the conclusion of the conference, a webcast replay will be available through the same link.

The Company will be available for one-on-one meetings during this conference. Interested investors should contact their Stifel representative to request meetings.

About X4 Pharmaceuticals

X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI® (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.

Company Contact:

José Juves

Head of Corporate & Patient Affairs

jose.juves@x4pharma.com

Investor Contact:

Daniel Ferry

Managing Director, LifeSci Advisors

daniel@lifesciadvisors.com

(617) 430-7576



Source: X4 Pharmaceuticals